WO2006114703A3 - Methode d'administration de (1s,s2)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yle)-1-propanol - Google Patents

Methode d'administration de (1s,s2)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yle)-1-propanol Download PDF

Info

Publication number
WO2006114703A3
WO2006114703A3 PCT/IB2006/001044 IB2006001044W WO2006114703A3 WO 2006114703 A3 WO2006114703 A3 WO 2006114703A3 IB 2006001044 W IB2006001044 W IB 2006001044W WO 2006114703 A3 WO2006114703 A3 WO 2006114703A3
Authority
WO
WIPO (PCT)
Prior art keywords
period
time
phenylpiperidin
hydroxyphenyl
administration
Prior art date
Application number
PCT/IB2006/001044
Other languages
English (en)
Other versions
WO2006114703A2 (fr
Inventor
Jerry John Weaver
Lorraine Yurkewicz
Keith David Wilner
Original Assignee
Pfizer Prod Inc
Jerry John Weaver
Lorraine Yurkewicz
Keith David Wilner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Jerry John Weaver, Lorraine Yurkewicz, Keith David Wilner filed Critical Pfizer Prod Inc
Publication of WO2006114703A2 publication Critical patent/WO2006114703A2/fr
Publication of WO2006114703A3 publication Critical patent/WO2006114703A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne, dans un aspect, une méthode pouvant améliorer chez l'être humain la biodisponibilité de (1S,S2)-1-(4-hydroxyphényl)-2-(4-hydroxy-4-phénylpipéridin-1-yle)-1-propanol, ou un sel pharmaceutiquement acceptable dudit composé. La méthode consiste à administrer à un être humain, sur une durée d'au moins 24 heures, (1S,S2)-1-(4-hydroxyphényl)-2-(4-hydroxy-4-phénylpipéridin-1-yle)-1-propanol ou un sel pharmaceutiquement acceptable dudit composé, cette durée représentant la durée totale d'une première durée et d'une seconde durée. Le taux d'administration sur la première durée est supérieur au taux d'administration sur la seconde durée. La biodisponibilité est améliorée par rapport à l'administration d'un taux constant égal au taux d'administration sur la seconde durée.
PCT/IB2006/001044 2005-04-25 2006-04-13 Methode d'administration de (1s,s2)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yle)-1-propanol WO2006114703A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67494705P 2005-04-25 2005-04-25
US60/674,947 2005-04-25

Publications (2)

Publication Number Publication Date
WO2006114703A2 WO2006114703A2 (fr) 2006-11-02
WO2006114703A3 true WO2006114703A3 (fr) 2007-03-22

Family

ID=36688172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001044 WO2006114703A2 (fr) 2005-04-25 2006-04-13 Methode d'administration de (1s,s2)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yle)-1-propanol

Country Status (1)

Country Link
WO (1) WO2006114703A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1186304A2 (fr) * 2000-09-06 2002-03-13 Pfizer Products Inc. Combinations pharmaceutiques pour le traitement d' attaques et de lésions traumatiques du cerveau

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1186304A2 (fr) * 2000-09-06 2002-03-13 Pfizer Products Inc. Combinations pharmaceutiques pour le traitement d' attaques et de lésions traumatiques du cerveau

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOHN A MCCAULEY: "NR2B subtype-selective NMDA receptor antagonists: 2001-2004", EXPERT OPINION, vol. 15, no. 4, 1 April 2005 (2005-04-01), pages 389 - 407, XP002392768, Retrieved from the Internet <URL:http://www.expertopin.com/doi/abs/10.1517/13543776.15.4.389> [retrieved on 20060627] *
JOHN. A. KEMP: "NMDA receptor pathways as drug targests", NATURE NEUROSCIENCE SUPPLEMENT, vol. 5, November 2002 (2002-11-01), pages 1039 - 1042, XP002392767, Retrieved from the Internet <URL:http://www.nature.com/neuro/journal/v5/n11s/pdf/nn936.pdf> [retrieved on 20060727] *
JOHNSON KIM ET AL: "Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers.", DRUG METABOLISM AND DISPOSITION: THE BIOLOGICAL FATE OF CHEMICALS. JAN 2003, vol. 31, no. 1, January 2003 (2003-01-01), pages 76 - 87, XP009069857, ISSN: 0090-9556, Retrieved from the Internet <URL:http://dmd.aspetjournals.org/cgi/reprint/31/1/76> [retrieved on 20060627] *
LORRAINE YURKEWICZ, JOURNAL OF NEUROTRAUMA, vol. 22, no. 12, December 2005 (2005-12-01), pages 1428 - 1443, XP002392769, Retrieved from the Internet <URL:http://www.liebertonline.com/doi/pdf/10.1089/neu.2005.22.1428> [retrieved on 20060727] *

Also Published As

Publication number Publication date
WO2006114703A2 (fr) 2006-11-02

Similar Documents

Publication Publication Date Title
WO2008027557A3 (fr) Compositions à base de topiramate et méthodes permettant d&#39;en augmenter la biodisponibilité
IL176689A0 (en) Use of memantine for the preparation of a medicament for the treatment of mild and mild-to-moderate alzheimer&#39;s disease
WO2006133941A3 (fr) Ingredient pharmaceutique actif a base de cannabinoides pour formes posologiques ameliorees
CA2427227A1 (fr) Compose de lactam
WO2004071529A3 (fr) Utilisations d&#39;anticorps contre le recepteur de facteur de croissance insulinoide i
WO2007025286A3 (fr) Methode d&#39;administration de medicaments pour traitement de la douleur trigeminale
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
WO2004028521A3 (fr) Composes organiques
WO2007002572A3 (fr) Nattokinase pour reduire la viscosite du sang total
HK1123213A1 (en) Reduction of dizziness, a side effect associated with pirfenidone therapy
WO2007064448A3 (fr) Traitement du cancer a l&#39;aide de fts et de 2-desoxyglucose
EP1938814A4 (fr) Produit pharmaceutique destine a proteger un nerf moteur chez les patients atteints de sclerose laterale amyotrophique
CA2632207C (fr) Utilisation de calcitonine pour traiter la pr
TW200616644A (en) Medicine for prevention or treatment of diabetes
WO2006115770A3 (fr) Preparations pharmaceutiques d&#39;olazanpine en comprimes a desintegration orale
WO2006045314A3 (fr) Utilisation d&#39;un secretagogue de l&#39;hormone de croissance en vue d&#39;accroitre ou de maintenir la masse maigre et/ou pour le traitement de la maladie pulmonaire obstructive chronique
WO2007133796A3 (fr) Procédés et compositions de traitement de l&#39;apnée du sommeil
WO2001089494A8 (fr) Procede d&#39;administration d&#39;un bisphosphonate
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
WO2006079077A3 (fr) Composes en tant que modulateurs de recepteur de ghreline et leurs utilisations
WO2005120518A3 (fr) Utilisation d&#39;analogues d&#39;atp pour le traitement des maladies cardio-vasculaires
WO2006026095A3 (fr) Composition et procede permettant une meilleure biodisponibilite et administration renforcee d&#39;acide 5,5 diphenyl-barbiturique au cerveau
MXPA06003122A (es) Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.
WO2005004854A3 (fr) Utilisation de la betaine pour le traitement des arterites
WO2005014032A3 (fr) Utilisations de secretagogues

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06727547

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6727547

Country of ref document: EP